Skip to Content
Merck
All Photos(1)

Key Documents

Y0001006

Dydrogesterone impurity B

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Pregna-4,6-diene-3,20-dione

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C21H28O2
CAS Number:
Molecular Weight:
312.45
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

dydrogesterone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1CC[C@@]2([C@@H]3[C@H]([C@H]4[C@@]([C@H](CC4)C(=O)C)(CC3)C)C=CC2=C1)C

InChI

1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1

InChI key

JGMOKGBVKVMRFX-LEKSSAKUSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dydrogesterone impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Zahiruddin Othman et al.
Menopause (New York, N.Y.), 18(11), 1219-1224 (2011-09-20)
The aim of this study was to evaluate the verbal learning and memory performance of postmenopausal women who received tualang honey (Agro Mas) in comparison with women receiving estrogen plus progestin therapy and untreated controls. A total of 102 postmenopausal
Ashalatha Ganesh et al.
Fertility and sterility, 95(6), 1961-1965 (2011-02-22)
To compare the efficacy of oral dydrogesterone with that of micronized vaginal P gel and micronized P capsule for luteal supplementation. Prospective, randomized clinical study. Institute of Reproductive Medicine, Kolkata, India. A total of 1,373 infertile women undergoing IVF participated.
Ireneusz Polac et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 27(9), 692-695 (2010-10-29)
Hormone therapy (HT) can be prothrombotic risk factor. We compared the effects of oral HT (o-HT) and transdermal HT (t-HT) on the kinetic of clot formation and fibrinolysis in postmenopausal women after 6 months HT using a multiparameter test. We
M V Suknovalova et al.
Eksperimental'naia i klinicheskaia farmakologiia, 76(7), 24-26 (2013-09-07)
It has been shown that specific binding of dydrogesterone with progesterone receptors in blood mononuclear cells of the patients included in the programs of in vitro fertilization, varies from 0 to 298%, thus at 38% of women dydrogesterone concedes to
A J Scheen et al.
Revue medicale de Liege, 66(4), 209-214 (2011-06-07)
Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service